NasdaqGM - Delayed Quote USD

EyePoint Pharmaceuticals, Inc. (EYPT)

17.50 -3.44 (-16.43%)
At close: April 18 at 4:00 PM EDT
18.18 +0.68 (+3.89%)
After hours: April 18 at 7:58 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Jay S. Duker M.D. President, CEO & Director 848.5k -- 1959
Dr. John B. Landis M.S., Ph.D. Interim Head of R&D and Director 63.75k -- 1953
Mr. Michael Pine Chief Business Officer 764.85k -- 1977
Mr. George O. Elston Executive VP & CFO 743.86k -- 1965
Mr. Michael J. Maciocio Senior Vice President of Manufacturing & Operations -- -- --
Mr. Ron I. Honig Esq. Chief Legal Officer & Company Secretary -- -- --
Ms. Jennifer Leonard Chief People Officer & Senior VP of IT -- -- --
Mr. David Scott Jones Senior VP & Chief Commercial Officer 672.08k -- 1968
Ms. Isabelle Lefebvre Chief Regulatory Officer -- -- --
Dr. Marcia Sellos-Moura Ph.D. Senior Vice President of Program Leadership -- -- --

EyePoint Pharmaceuticals, Inc.

480 Pleasant Street
Suite A-210
Watertown, MA 02472
United States
617 926 5000 https://eyepointpharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
121

Description

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Corporate Governance

EyePoint Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 9; Board: 3; Shareholder Rights: 4; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 01, 2024 - May 06, 2024
EyePoint Pharmaceuticals, Inc. Earnings Call

Related Tickers

OCUL Ocular Therapeutix, Inc.
5.86
-22.69%
 
FDMT 4D Molecular Therapeutics, Inc.
24.78
-2.06%
 
EYEN Eyenovia, Inc.
0.5309
-1.56%
 
ADVM Adverum Biotechnologies, Inc.
11.15
-1.76%
 
DNTH Dianthus Therapeutics, Inc.
23.63
+1.24%
 
EWTX Edgewise Therapeutics, Inc.
15.45
-1.28%
 
ALXO ALX Oncology Holdings Inc.
15.74
-2.11%
 
ELVN Enliven Therapeutics, Inc.
17.67
+2.14%
 
CGEM Cullinan Therapeutics, Inc.
18.06
+1.01%
 
CLSD Clearside Biomedical, Inc.
1.3200
+4.76%